Picture of Hyperion DeFi logo

HYPD — Hyperion DeFi News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals

Aug 16 (Reuters) - Eyenovia Inc  EYEN.O :
    * EYENOVIA ACQUIRES U.S. COMMERCIAL RIGHTS TO APP13007
(CLOBETASOL
PROPIONATE OPHTHALMIC NANOSUSPENSION, 0.05%) FROM FORMOSA
PHARMACEUTICALS
    * EYENOVIA INC - PLANS TO EVALUATE NOVEL CLOBETASOL
FORMULATIONS
IN ITS PROPRIETARY OPTEJET DISPENSING PLATFORM AS A POTENTIAL
TREATMENT FOR DRY EYE

Source text for Eikon:  ID:nGNX2kmW89 
Further company coverage:  EYEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Hyperion DeFi

See all news